Musculoskeletal Disorders

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Musculoskeletal Disorders Resource Center

Welcome to the MPR Musculoskeletal Disorders Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Instrumented Spinal Fusion Method Impacts Infection Rate

For patients who undergo instrumented spinal fusion, the rates of infection are higher among those who receive posterior lumbar interbody fusion compared with those who receive posterior or posterolateral fusion.

Increase in Physical Activity in Men Optimizes Peak Bone Mass

For young men, increasing physical activity over a five-year period is associated with improvements in bone mineral content (BMC) and bone mineral density (BMD).

Gender, High DAS28-P Index Predictive of Pain in Early RA

For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness and visual analog score) (DAS28-P) at baseline are predictive of less improvement in pain at one year.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events (SREs), and pain, but bisphosphonates do not appear to improve overall survival (OS), with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving OS.

Lowest Fused Vertebral Level Linked to Motion in Scoliosis

For postoperative patients with adolescent idiopathic scoliosis (AIS), preservation of vertebral motion segments allows for greater distribution of functional motion.

EXPAREL

4/23/2012

Pacira Pharmaceuticals

Pharmacological Class: Local anesthetic (amide-type).

Active Ingredient(s): Bupivacaine 13.3mg/mL; liposome injectable suspension; preservative-free.

Indication: For administration into the surgical site to produce postsurgical analgesia.

DUEXIS

1/8/2012

Horizon Pharma

Pharmacological Class: NSAID + H₂ blocker.

Active Ingredient(s): Ibuprofen 800mg, famotidine 26.6mg; tabs.

Indication: Relief of signs/symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers (eg, gastric and/or duodenal ulcer), in patients who are taking ibuprofen for those indications.

XGEVA

12/23/2010

Amgen, Inc.

Pharmacological Class: Osteoclast inhibitor (RANKL inhibitor)

Active Ingredient(s): Denosumab 120mg/vial (70mg/mL); soln for SC inj; preservative-free.

Indication: Prevention of skeletal-related events (SRE) in patients with bone metastases from solid tumors. Not for preventing SRE with multiple myeloma.